---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-077616"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2024-06-26T23:59:59+00:00"
generated_at: "2026-06-01T02:03:15.346484+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "low"
source: SEC EDGAR
---

# FibroGen hosts KOL event on FG-3246 for metastatic castration-resistant prostate cancer

## Summary
- June 26, 2024: FibroGen and UCSF's Dr. Rahul Aggarwal presented on FG-3246 development program for mCRPC.
- Presentation covers unmet need, evolving treatment landscape, and clinical development plans for FG-3246.
- No financial results or new clinical data disclosed in the filing or the included exhibit.
- Forward-looking statements caution that FG-3246 program involves substantial risks and uncertainties.

## SEC filing metadata
- accession: 0000950170-24-077616
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2024-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000095017024077616/0000950170-24-077616-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000095017024077616/fgen-20240626.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-077616
- JSON: https://secwatch.observer/filing/0000950170-24-077616.json
- Plain text: https://secwatch.observer/filing/0000950170-24-077616.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.